MIAMI, Feb. 22, 2018 /PRNewswire/ -- Abarca, a pharmacy benefit manager that is disrupting the industry with smarter
"In the future, our payers and members will only pay for therapies that deliver expected outcomes and provide meaningful clinical value," said Jason Borschow, Abarca's Chief Executive Officer. "We are proud to partner with Amgen, a company that stands by its products, to make this a reality today for the clients and members we serve."
Repatha is a PCSK9 inhibitor indicated to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease. Recently, Abarca also announced an outcomes-based contract with Biogen for medications used to treat multiple sclerosis. Abarca is currently collaborating with several drug manufacturers for similar agreements.
Abarca is a different kind of company that rejects traditional PBM thinking, and its aggressive push for outcomes-based contracts is just one example. Abarca's smarter technology platform focuses on delivering a better experience for members and plans, and its higher standard of business practices also set it apart from the industry. Founded more than a decade ago, today Abarca serves more than two million members and manages more than a billion dollars in drug spend.
"Our business philosophy is simple: Put our clients and members first in everything we do," concluded Borschow. "When that is your priority, the decision to pursue value-based agreements suddenly becomes an obvious one."
About Abarca Abarca is igniting a revolution in healthcare. It started by redefining pharmacy benefits, but this is just the beginning. It is built on the belief that there is a better way for people and companies to work together, connect with each other, and spread healthy living across the planet. With smarter technology and a straightforward approach to business, Abarca provides a much better experience and greater value for payers and consumers. For nearly a decade, they have challenged many industry conventions and trampled on a few. So call them a PBM for discussion purposes, but they are unlike any other company out there. Join the revolution at abarcahealth.com.
View original content:http://www.prnewswire.com/news-releases/abarca-amgen-enter-outcomes-based-agreement-for-repatha-evolocumab-300602882.html
Subscribe to our Free Newsletters!
Take the quiz on Rabies and test your knowledge about this infection that can affect the brain ...
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...View All